Literature DB >> 2155763

The value of screening and central registration of families with familial adenomatous polyposis. A study of 82 families in The Netherlands.

H F Vasen1, G Griffioen, G J Offerhaus, F C Den Hartog Jager, I S Van Leeuwen-Cornelisse, P Meera Khan, C B Lamers, E A Van Slooten.   

Abstract

In 1984 a national registry of families with familial adenomatous polyposis was set up in The Netherlands to promote screening in those families. Eight-two families had been registered by the end of 1988. Analysis of the pedigrees showed that 204 family members at risk had not yet been screened. The diagnosis of familial adenomatous polyposis was histologically confirmed in 230 patients. These patients were subdivided into two groups. Group A comprised patients with familial adenomatous polyposis referred because they were symptomatic, and Group B relatives of these patients who were found by screening to have familial adenomatous polyposis. The authors compared these groups with respect to the occurrence of colorectal carcinoma. Fifty-four patients were found to have a colorectal carcinoma at the time of diagnosis of familial adenomatous polyposis, i.e., 49 of the 104 patients in Group A (47 percent) and five of the 126 patients in Group B (4 percent). The average age at diagnosis of the 104 patients in Group A was 35 years (range, 13 to 66 years) and that of the 126 patients in Group B was 24 years (range, 8 to 59 years). By the age of 40 years, 90 percent of the patients in group B had been diagnosed. Late onset of familial adenomatous polyposis was found in four families. Endoscopy and/or radiography of the upper digestive tract were (was) performed in 44 of the 230 patients. Nineteen patients (43 percent) were found to have polyps in the stomach or duodenum, or both. In our series, only one patient died from cancer of the upper digestive tract (ampullary carcinoma). These results show conclusively that screening leads to the early detection of familial adenomatous polyposis. The value of a national registry is proved by the finding of many at-risk family members who had not previously been screened. Screening should start between the ages of 10 and 12 and should continue up to the age of 50. In the rare cases of families with an apparently late onset of familial adenomatous polyposis, screening should be continued up to age 60. More studies are needed to determine the natural history of polyps in the upper digestive tract.

Entities:  

Mesh:

Year:  1990        PMID: 2155763     DOI: 10.1007/BF02134185

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  27 in total

Review 1.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

2.  Evaluating causes of death in familial adenomatous polyposis.

Authors:  Fábio Guilherme C M de Campos; Rodrigo Oliva Perez; Antônio Rocco Imperiale; Víctor Edmond Seid; Sérgio Carlos Nahas; Ivan Cecconello
Journal:  J Gastrointest Surg       Date:  2010-07-30       Impact factor: 3.452

3.  Severe colonic dysplasia in a child with familial adenomatous polyposis.

Authors:  D Ruttenberg; M S Elliot; E Bolding
Journal:  Int J Colorectal Dis       Date:  1991-08       Impact factor: 2.571

Review 4.  Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management.

Authors:  Priyanka Kanth; Jade Grimmett; Marjan Champine; Randall Burt; N Jewel Samadder
Journal:  Am J Gastroenterol       Date:  2017-08-08       Impact factor: 10.864

5.  Diagnosis of familial adenomatous polyposis.

Authors:  S Bülow
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

6.  Evaluation of molecular genetic diagnosis in the management of familial adenomatous polyposis coli: a population based study.

Authors:  E R Maher; D E Barton; R Slatter; D J Koch; M H Jones; H Nagase; S J Payne; S J Charles; A T Moore; Y Nakamura
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

7.  Frequent polymorphism in the 13th exon of the adenomatous polyposis coli gene.

Authors:  S Olschwang; P Laurent-Puig; B Thuille; G Thomas
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

8.  Value of combined phenotypic markers in identifying inheritance of familial adenomatous polyposis.

Authors:  F M Giardiello; G J Offerhaus; E I Traboulsi; J C Graybeal; I H Maumenee; A J Krush; L S Levin; S V Booker; S R Hamilton
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

9.  The UK Northern region genetic register for familial adenomatous polyposis coli: use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations.

Authors:  J Burn; P Chapman; J Delhanty; C Wood; F Lalloo; M B Cachon-Gonzalez; K Tsioupra; W Church; M Rhodes; A Gunn
Journal:  J Med Genet       Date:  1991-05       Impact factor: 6.318

10.  APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis.

Authors:  R B van der Luijt; H F Vasen; C M Tops; C Breukel; R Fodde; P Meera Khan
Journal:  Hum Genet       Date:  1995-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.